Investigating brain activity related to walking in Parkinson's patients
Investigating Neural Biomarkers for Gait in Parkinson's Patients
Swiss Federal Institute of Technology · NCT05820074
This study looks at how the brains of people with Parkinson's disease work while they walk to see if it can help create better treatments for their movement problems.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 60 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Swiss Federal Institute of Technology (other) |
| Locations | 1 site (Vitznau, Canton of Lucerne) |
| Trial ID | NCT05820074 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the neural mechanisms involved in movement among individuals with Parkinson's disease. Participants will engage in walking and gait-related tasks while their brain activity is recorded to identify neural biomarkers associated with gait. The study includes 60 participants, split evenly between healthy individuals and those with Parkinson's disease, to compare neural activity during different motor tasks. Insights gained may lead to personalized treatment options for managing gait disorders in Parkinson's patients.
Who should consider this trial
Good fit: Ideal candidates include non-tremor dominant idiopathic Parkinson's patients with postural instability and gait disturbances who have an implanted Percept™ PC neurostimulator.
Not a fit: Patients with relevant cognitive impairments or those with other neurological or orthopedic conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more personalized and effective treatment strategies for gait disorders in Parkinson's disease.
How similar studies have performed: Other studies have shown promise in identifying neural biomarkers for movement disorders, suggesting that this approach may yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: All participants * must have given informed consent as documented by signature * agree to comply with the study procedures Healthy control group * no neurological, orthopedic, or rheumatologic disease history * no identified sensory impairment. * no epilepsy and self-diagnosed acute or chronic psychiatric disorders Parkinson's Patients * non-tremor dominant idiopathic PD patients * presence of postural instability (UPDRS \>1 for postural instability \[17\]), gait disturbance, and absence of other causes of reduced balance * Implanted with Percept™ PC neurostimulator * Able to be in the stimulation OFF Exclusion Criteria: * Relevant cognitive impairment, with a score on Montréal Cognitive Assessment (MoCA) \< 20 * History of physical or neurological condition that interferes with study procedures * Social and/or personal circumstances interfering with the ability to come to the session
Where this trial is running
Vitznau, Canton of Lucerne
- Cereneo — Vitznau, Canton of Lucerne, Switzerland (RECRUITING)
Study contacts
- Principal investigator: Olivier Lambercy, PhD — RELab, ETH Zürich
- Study coordinator: Lena Salzmann, MSc
- Email: lena.salzmann@hest.ethz.ch
- Phone: +41788248679
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Parkinson Disease, Gait Disorders, Neurologic, Parkinson's disease, gait parameters, neural activity, Percept PC, deep brain stimulation